Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Advertisement - Audited Financial Results for the quarter and year ended March 31, 202326-05-2023
26-05-2023
Strides Pharma Science Ltd - 532531 - Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Disclosure of Related Party Transactions pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201525-05-2023
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio Recording of Earnings call pertaining to the Financial Results for the quarter and year ended March 31, 2023.25-05-2023
Strides Pharma Science Ltd - 532531 - Submission Of Statement Of Deviation/ Variation Pursuant To Regulation 32 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Submission of Statement of Deviation/ Variation pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201525-05-2023
Q4FY23 Quarterly & FY23 Annual Result Announced for Strides Pharma Science Ltd.
Strides Pharma Science announced Q4FY23 & FY23 results: Q4FY23: Record quarterly sales of Rs 9,904 million in Q4FY23, up 14% QoQ and YoY Q4FY23 gross margins at 59.5%, up 868bps YoY, returning closer to the historical peak of ~60% Q4FY23 EBITDA at Rs 1,596 million, a 33% sequential increase, and among Company’s best quarters on an absolute number basis Q4FY23 EBITDA margins at 16.1%, trending positively towards the company's historical ~20% margins Q4FY23 adjusted1 PAT at Rs 341 million The US business reported third consecutive quarter of USD 60+ million in revenues Other regulated markets (ORM) recorded the highest quarterly sales of USD 48 million in Q4FY23. The Board has recommended a dividend of Rs 1.5 per share FY23: Reports highest-ever annual sales of Rs 37,042 million, a 20% increase YoY. FY23 gross margins at 56.1%, absolute gross margin increase of Rs 4,850 million in FY23 FY23 EBITDA at Rs 4,460 million, an increase of Rs 4,418 million over FY22 EBITDA. FY23 Adjusted1 PAT of Rs 714 million; reported PAT impacted by one-time impairment at Stelis mainly related to Sputnik US business sales at USD 232 million, an all-time high for Strides, increased 58% YoY from USD 157 million in FY22. Other Regulated Markets (ORM) reported its highest sales at USD 157 million, growing 12% YoY Four Successful closures of USFDA audits, including the lifting of the Warning Letter issued in 2019 for the Company’s Puducherry facility. Arun Kumar, Founder, Executive Chairperson & Managing Director, commented on the performance and said, “We are pleased to conclude FY23 on an encouraging note. The stated plan to return to growth, enhance profitability, and reduce debt has made significant headway. From FY22 to FY23, our total revenues increased by 20%, aided by performance in regulated markets. The US market, led by new product introductions and solid base performance, generated its highest-ever revenue of USD 232 million with significant margin expansion, in line with the management outlook. The other regulated markets also performed well throughout the year and reported their highest sales. The front-end markets in the United Kingdom and the Nordics performed as anticipated, and the B2B markets grew further due to our renewed focus from the beginning of the year. On the operational front, we are delighted to announce that the USFDA has recently reclassified our Puducherry facility, giving all of our manufacturing sites a clear compliance status by the agency On the bottom line, we saw an improvement in gross margin of 463 basis points for the year with an increase in EBITDA margin of 1190 basis points to 12.0%. The fourth quarter saw our exit EBITDA margins rise to 16.1% from 5.3% in the corresponding period last fiscal year. With the receipt of Arrotex proceeds and cash from operations, our total gross debt has reduced in FY23, and Net debt to Q4FY23 Annualized EBITDA was at 3.4x, nearing the targeted net debt to EBITDA of under 3x. We are confident in continuing FY23's growth momentum and are on track to continuously improve the quality of our earnings while strengthening our balance sheet in FY24.” Result PDF25-05-2023
Strides Pharma Science Ltd - 532531 - Grant Of Options Under Strides ESOP Plan 2016
Grant of Options under Strides ESOP Plan 201625-05-2023
Strides Pharma Science Ltd - 532531 - Corporate Action-Board approves Dividend
Outcome of Board Meeting - Audited Financial Results (Standalone & Consolidated) for quarter and year ended March 31, 202325-05-2023
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Strides reports strong Q4FY23 results and lays the foundation for a promising FY2425-05-2023
Strides Pharma Science Ltd - 532531 - Outcome Of Board Meeting - Audited Financial Results (Standalone & Consolidated) For Quarter And Year Ended March 31, 2023
Outcome of Board Meeting - Audited Financial Results (Standalone & Consolidated) for quarter and year ended March 31, 202325-05-2023